Home » Features » Companies » Sysmex


About Sysmex

Sysmex Corporation is a global supplier of clinical laboratory testing devices, reagents and software for hematology, hemostasis, immuno-chemistry, particle counting and urinalysis. Sysmex Corporation is distributing its comprehensive products in more than 125 countries and counted as one of the top ten diagnostics companies worldwide. Sysmex Corporation is a technology oriented company and committed to contribute to a healthy society by developing innovative technologies for clinical laboratory testing as well as new core technologies in life sciences.

Sysmex in News

Molecular Diagnostics Market Worth $9.50 Billion by 2022: Grand View Research, Inc.
The global molecular diagnostics market is expected to reach over USD 9.50 billion by 2022, according to a new report by Grand View Research Inc. Growing prevalence of chronic diseases and infections such as HPV and influenza is anticipated to be the key driver for molecular diagnostics market growth

CellaVision AB: Interim report January-March 2015
Continued growth and strong operating margin

CellaVision Year-end bulletin 2014
Year-end bulletin 2014 Strongest quarter in CellaVision's history and first major veterinary order.

CellaVision AB: Interim Report January-September 2014
Continued strong sales trend in Europe and North America. Zlatko Rihter appointed President/CEO.

Two New Clinical Studies Show Masimo Noninvasive Hemoglobin (SpHb(R)) Demonstrated Similar Precision as Hemoglobin From Point of Care Devices
Masimo (NASDAQ: MASI) announced two new studies today that showed that noninvasive hemoglobin (SpHb®) demonstrated similar accuracy as hemoglobin measured by invasive hemoglobin analyzers when both SpHb and the invasive hemoglobin analyzer were compared to laboratory hematology analyzer.

Global In Vitro Diagnostics (POC/Rapid Diagnostics) Market - Forecast to 2019
Research and Markets ( has announced the addition of the "In Vitro Diagnostics (POC/Rapid diagnostics) Global market - Forecast to 2019" report to their offering.

CellaVision AB: Interim report January-March 2014
Strong cash flow and successful product development January 1-March 31 2014

CellaVision Year-end bulletin 2013
Strong close to 2013

CellaVision AB: Interim report January - September 2013
Strong sales and substantial improvement in earnings in the third quarterJanuary 1 - September 30, 2013

Windsor Regional Hospital in Canada Acquires Revolutionary Sysmex(R) XN-Series(TM) Hematology Analyzers
Windsor Regional Hospital, a multi-site community hospital that provides acute care services to Windsor and Essex County, and Sysmex Canada, Inc., a wholly-owned subsidiary of Sysmex America, Inc., today announced the addition of the new state-of-the-art Sysmex® XN-Series™ Hematology Analyzers in Windsor's clinical laboratories

Sysmex Canada BOD Elects Robert Edward Degnan as President and COO, Nick Kawato as Secretary
Sysmex Canada, Inc., a wholly-owned subsidiary of Sysmex America, Inc., today announced that its Board of Directors has elected Robert Edward Degnan as President and Chief Operating Officer, and Shinichi (Nick) Kawato as Secretary for the Board of Directors, effective immediately. Both men will report directly to John Kershaw, President & Chief Executive Officer, Sysmex America, Inc

Brockville General Hospital Acquires Canada's First State-of-the-Art Sysmex XN-2000(TM) Automated Hematology Analyzer
Ontario-based Brockville General Hospital and Sysmex Canada, Inc. today announced the hospital's installation and implementation of a Sysmex XN-2000™ Automated Hematology Analyzer. This is the first analyzer of the new Sysmex® XN-Series suite of products to be installed in Canada

CellaVision and Sysmex announce a jointly-developed product for hematology labs
This information was released for public disclosure on April 16, 2013 at 3.00 pm CET. CellaVision today announced that the company and its partner Sysmex have co-developed a product which integrates CellaVision Digital Cell Morphology technology with the Sysmex XN-series hematology platform. The product, DI-60, will be part of the global Sysmex product portfolio for hematology laboratories.

Coagulation Testing Market to Jump to Over $1.9 Billion by 2018 cites in its newly published "Coagulation Testing Markets" report that the coagulation testing market will jump to over $1.9 billion by 2018. For more information, visit:

Sysmex America Announces FDA Clearance of XN-Series Hematology Analyzers
Sysmex America, Inc. and Sysmex Corporation, Kobe, Japan, today announce the United States Food and Drug Administration's (FDA) clearance of the Sysmex® XN-Series Hematology Analyzers. Sysmex previously received a Medical Device License for the analyzers from Health Canada

Diagnostic Testing, Medical Imaging and Pharmaceutical Markets to See Dramatic Growth cites in its newly updated market research report bundles that the diagnostic testing, medical imaging and pharmaceutical markets will see dramatic growth. For more information, visit:

Worldwide IVD Market to Catapult to $82 Billion by 2017 cites in its newly published "Clinical Laboratory Testing Volume 1: IVD Reagents and Instruments Markets" report that the worldwide IVD market will catapult to $82 billion by 2017. For more information, visit:

New President of CellaVision North America
CellaVision AB (publ) has appointed Peter Wilson as President CellaVision North America with responsibility for operations in the U.S. and Canada. Peter Wilson currently holds a position as Marketing Manager and is part of the CellaVision Management Team. He will begin his new position on September 1, 2012

Global Flow Cytometry Market to Jump to $4.9 Billion by 2017 cites in its newly published "Global Flow Cytometry Markets" report that the global flow cytometry market will jump to $4.9 billion by 2017. For more information, visit:

Sysmex Canada Adds Industry Veteran to Employee Roster
Sysmex Canada, Inc., a wholly-owned subsidiary of Sysmex America, Inc., today announces the appointment of Michael Spence as the company's Director of Sales. Spence's areas of responsibilities include sales, relationship management, contract negotiation, and oversight of the company's Health System Account Managers

CellaVision AB (publ) Interim report January - September 2011
Substantially improved earnings and continued high growth

Sysmex Canada Technology Allows Diagnostic Services of Manitoba to Standardize Hematology Services
Toronto-based Sysmex Canada, Inc. today announced exclusive eight-year Vendor Supply and Capital Equipment Service Agreements with Diagnostic Services of Manitoba. "Sysmex technology will allow DSM to standardize hematology instruments, reagents, training, services and support for the public laboratories within its network," said Carl Rocha, General Manager, Sysmex Canada, Inc

Comment on this story